These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 36527039)

  • 1. A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study.
    Eriksen M; Pfeiffer P; Rohrberg KS; Yde CW; Petersen LN; Poulsen LØ; Qvortrup C
    BMC Cancer; 2022 Dec; 22(1):1321. PubMed ID: 36527039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study.
    Gallois C; Bergen ES; Auclin É; Pernot S; Higué J; Trouilloud I; Touchefeu Y; Turpin A; Mazard T; Sartore-Bianchi A; Prenen H; Alberti A; Pilla L; Cuissy S; Wookey V; Perret A; Melchior C; Artru P; Dubreuil O; Drouillard A; Doat S; Lavolé J; Basile D; Perkins G; Jary M; Stintzing S; Ros J; Tougeron D; Taieb J
    ESMO Open; 2024 Sep; 9(9):103696. PubMed ID: 39255538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With
    Van Cutsem E; Huijberts S; Grothey A; Yaeger R; Cuyle PJ; Elez E; Fakih M; Montagut C; Peeters M; Yoshino T; Wasan H; Desai J; Ciardiello F; Gollerkeri A; Christy-Bittel J; Maharry K; Sandor V; Schellens JHM; Kopetz S; Tabernero J
    J Clin Oncol; 2019 Jun; 37(17):1460-1469. PubMed ID: 30892987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated
    Van Cutsem E; Taieb J; Yaeger R; Yoshino T; Grothey A; Maiello E; Elez E; Dekervel J; Ross P; Ruiz-Casado A; Graham J; Kato T; Ruffinelli JC; André T; Carrière Roussel E; Klauck I; Groc M; Vedovato JC; Tabernero J
    J Clin Oncol; 2023 May; 41(14):2628-2637. PubMed ID: 36763936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The BEETS (JACCRO CC-18) trial: an observational and translational study of
    Inagaki C; Matoba R; Yuki S; Shiozawa M; Tsuji A; Inoue E; Muro K; Ichikawa W; Fujii M; Sunakawa Y
    Future Oncol; 2023 Jun; 19(17):1165-1174. PubMed ID: 37458152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR
    Elez E; Kopetz S; Tabernero J; Bekaii-Saab T; Taieb J; Yoshino T; Manji G; Fernandez K; Abbattista A; Zhang X; Morris VK
    Future Oncol; 2024 Apr; 20(11):653-663. PubMed ID: 37815847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience.
    Boccaccino A; Borelli B; Intini R; Antista M; Bensi M; Rossini D; Passardi A; Tamberi S; Giampieri R; Antonuzzo L; Noto L; Roviello G; Zichi C; Salati M; Puccini A; Noto C; Parisi A; Rihawi K; Persano M; Crespi V; Libertini M; Giordano M; Moretto R; Lonardi S; Cremolini C
    ESMO Open; 2022 Jun; 7(3):100506. PubMed ID: 35696748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Encorafenib in Combination With Cetuximab After Systemic Therapy in Patients With BRAF
    Stintzing S; Seufferlein T; Rosé C; Reichenbach F; Lüftner D
    Clin Colorectal Cancer; 2022 Sep; 21(3):244-251. PubMed ID: 35654691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAF
    Kotani D; Takashima A; Kato T; Satoh T; Masuishi T; Komatsu Y; Shiozawa M; Esaki T; Izawa N; Takeuchi S; Bando H; Iwasa S; Hasegawa H; Yamaguchi T; Taniguchi H; Ushida Y; Oizaki T; Inoue C; Yoshino T
    Clin Colorectal Cancer; 2024 Jun; 23(2):174-182.e6. PubMed ID: 38553360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRESBIEN (OGSG 2101): encorafenib, binimetinib and cetuximab for early recurrent stage II/III
    Boku S; Satake H; Ohta T; Mitani S; Kawakami K; Suzuki Y; Matsumoto T; Terazawa T; Yamazaki E; Hasegawa H; Ikoma T; Uemura M; Yamaguchi T; Naito A; Ishizuka Y; Kurokawa Y; Sakai D; Kawakami H; Shimokawa T; Tsujinaka T; Kato T; Satoh T; Kagawa Y
    Future Oncol; 2022 Dec; 18(38):4153-4160. PubMed ID: 36475784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study.
    Tabernero J; Velez L; Trevino TL; Grothey A; Yaeger R; Van Cutsem E; Wasan H; Desai J; Ciardiello F; Yoshino T; Gollerkeri A; Maharry K; Christy-Bittel J; Kopetz S
    ESMO Open; 2021 Dec; 6(6):100328. PubMed ID: 34896698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of
    Stintzing S; Heinrich K; Tougeron D; Modest DP; Schwaner I; Eucker J; Pihusch R; Stauch M; Kaiser F; Kahl C; Karthaus M; Müller C; Burkart C; Reinacher-Schick A; Kasper-Virchow S; Fischer von Weikersthal L; Krammer-Steiner B; Prager GW; Taieb J; Heinemann V
    J Clin Oncol; 2023 Sep; 41(25):4143-4153. PubMed ID: 37352476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E Mutation.
    Al-Salama ZT
    Drugs; 2021 May; 81(7):849-856. PubMed ID: 33914242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse Events Associated with Encorafenib Plus Cetuximab in Patients with BRAFV600E-mutant Metastatic Colorectal Cancer: An in-depth Analysis of the BEACON CRC Study.
    Taieb J; Lonardi S; Desai J; Folprecht G; Gallois C; Marques EP; Khan S; Castagné C; Wasan H
    Clin Colorectal Cancer; 2023 Mar; 22(1):59-66. PubMed ID: 36653241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Encorafenib, Binimetinib, and Cetuximab in
    Kopetz S; Grothey A; Yaeger R; Van Cutsem E; Desai J; Yoshino T; Wasan H; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Pfeiffer P; Orlov S; Lonardi S; Elez E; Kim TW; Schellens JHM; Guo C; Krishnan A; Dekervel J; Morris V; Calvo Ferrandiz A; Tarpgaard LS; Braun M; Gollerkeri A; Keir C; Maharry K; Pickard M; Christy-Bittel J; Anderson L; Sandor V; Tabernero J
    N Engl J Med; 2019 Oct; 381(17):1632-1643. PubMed ID: 31566309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated
    Tabernero J; Grothey A; Van Cutsem E; Yaeger R; Wasan H; Yoshino T; Desai J; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Elez E; Gollerkeri A; Maharry K; Christy-Bittel J; Kopetz S
    J Clin Oncol; 2021 Feb; 39(4):273-284. PubMed ID: 33503393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer.
    Kotani D; Bando H; Taniguchi H; Masuishi T; Komatsu Y; Yamaguchi K; Nakajima T; Satoh T; Nishina T; Esaki T; Nomura S; Takahashi K; Iida S; Matsuda S; Motonaga S; Fuse N; Sato A; Fujii S; Ohtsu A; Ebi H; Yoshino T
    ESMO Open; 2020; 5(1):e000624. PubMed ID: 33551068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases.
    Kobayashi S; Bando H; Taketomi A; Takamoto T; Shinozaki E; Shiozawa M; Hara H; Yamazaki K; Komori K; Matsuhashi N; Kato T; Kagawa Y; Yokota M; Oki E; Komine K; Takahashi S; Wakabayashi M; Yoshino T
    BMC Cancer; 2023 Aug; 23(1):779. PubMed ID: 37605122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA.
    Li S; Hu H; Ding D; Zhu Y; Huang J
    Adv Ther; 2021 Mar; 38(3):1650-1659. PubMed ID: 33569738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of
    Ros J; Rodríguez-Castells M; Saoudi N; Baraibar I; Salva F; Tabernero J; Élez E
    Expert Rev Anticancer Ther; 2023; 23(8):797-806. PubMed ID: 37482749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.